Seattle Genetics Inc (NASDAQ:SGEN) reports that they have entered Phase I into their immunology agent, SEA-CD40, to act on various types of solid tumors in cancer patients. This along with other ongoing studies the company is involved in creates a company with its fingers in many pies, a solid pipeline of opportunities.
Seattle Genetics’ (NASDAQ:SGEN) drug SEA-CD40 has said that preclinical data has shown the capability of the drug to stimulate the immune system to fight cancer and they will therefore enter phase I trials in patients with advanced tumors. The study will main reason for the trials at this stage are to evaluate the safety profile and maximum dose tolerance of the drug. Being at phase I trials, the drug is obviously a long way off commercialization at this stage.
In addition to this Seattle Genetics (NASDAQ:SGEN) has a further six development stage drugs in the pipeline for the treatment of cancer, in addition to a large number of studies into the treatment of Hodgkin’s lymphoma.
As such, Seattle Genetics has a lot of drugs in the pipeline which means they have many possibilities and are well diversified that some of them may come to commercialization.
Investors should keep a focus on updates from the company to see how the trials are progressing and adjust their holdings of SGEN accordingly and of course recognise drug development companies are very risky investments.
Seattle Genetics (NASDAQ:SGEN) finished trading yesterday at $34.14, having jumped up 5.01%. SGEN has a trailing 12 month earnings per share of -$0.62 with an EPS estimate next year of -$0.33.